Tavapadon for parkinson disease

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 3 trial. Large late-stage trial in people. As of 19 Nov 2026, from 7 registered trials.

Why this status

  1. 13 Dec 2019: Trial started, NCT04201093
  2. 17 Dec 2019: Trial registered, NCT04201093
  3. 6 Jan 2020: Trial started, NCT04223193
  4. 10 Jan 2020: Trial registered, NCT04223193
  5. 9 Sep 2020: Trial registered, NCT04542499
  6. 23 Sep 2020: Trial started, NCT04542499
  7. 18 Feb 2021: Trial registered, NCT04760769
  8. 24 Feb 2021: Trial started, NCT04760769

The trials

NCT02224664: Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of PF-06649751 in Parkinson's Disease

State
Completed
Phase
Phase 1
People
50 taking part
Started
Oct 2014
Primary completion
Mar 2016
Arms
Cohort 3, Cohort 4, Cohort 5, Cohort 6
Results
Posted on the registry
Papers
doi:10.1007/s40120-018-0114-z
  1. 25 Aug 2014: Trial registered
  2. 27 Mar 2017: Trial results posted

NCT02847650: Efficacy, Safety and Tolerability of PF-06649751 in Parkinson's Disease Patients at Early Stage of the Disease

State
Stopped early
Phase
Phase 2
People
57 taking part
Started
17 Oct 2016
Primary completion
29 Jan 2018
Arms
PF-06649751
Results
Posted on the registry
Papers
doi:10.1177/1756286420911296
  1. 28 Jul 2016: Trial registered
  2. 17 Oct 2016: Trial started
  3. 29 Jan 2018: Trial terminated
  4. 15 Jan 2019: Trial results posted

NCT04201093: Fixed-Dose Trial in Early Parkinson's Disease (PD)

State
Completed
Phase
Phase 3
People
529 taking part
Started
13 Dec 2019
Primary completion
28 Jun 2024
Arms
Tavapadon 5 mg, Tavapadon 15 mg
Results
Posted on the registry
Papers
doi:10.1001/jamaneurol.2026.0590
  1. 13 Dec 2019: Trial started
  2. 17 Dec 2019: Trial registered
  3. 28 Jun 2024: Trial completed
  4. 28 Jul 2025: Trial results posted

NCT04223193: Flexible-Dose Trial in Early Parkinson's Disease (PD)

State
Completed
Phase
Phase 3
People
304 taking part
Started
6 Jan 2020
Primary completion
1 Oct 2024
Arms
Tavapadon
Results
Posted on the registry
Papers
doi:10.1016/s1474-4422(26)00215-2
  1. 6 Jan 2020: Trial started
  2. 10 Jan 2020: Trial registered
  3. 1 Oct 2024: Trial completed
  4. 21 Nov 2025: Trial results posted

NCT04542499: Flexible-Dose, Adjunctive Therapy Trial in Adults With Parkinson's Disease With Motor Fluctuations (TEMPO-3)

State
Completed
Phase
Phase 3
People
507 taking part
Started
23 Sep 2020
Primary completion
29 Jan 2024
Arms
Tavapadon
Results
Posted on the registry
Papers
doi:10.1001/jamaneurol.2026.0577
  1. 9 Sep 2020: Trial registered
  2. 23 Sep 2020: Trial started
  3. 15 Feb 2024: Trial completed
  4. 25 Mar 2025: Trial results posted

NCT04760769: Open-label Trial in Parkinson's Disease (PD)

State
Completed
Phase
Phase 3
People
992 taking part
Started
24 Feb 2021
Primary completion
1 Dec 2025
Arms
Tavapadon
Results
None posted
  1. 18 Feb 2021: Trial registered
  2. 24 Feb 2021: Trial started
  3. 1 Dec 2025: Trial completed

NCT05610189: Multiple-dose Trial to Determine the Clinical Bioequivalence Between Tavapadon Tablets in Participants With Parkinson's Disease

State
Completed
Phase
Phase 1
People
25 taking part
Started
15 Dec 2022
Primary completion
12 Dec 2023
Arms
Cohort 1: Tavapadon 1x15 mg Followed by 3x5 mg, Cohort 2: Tavapadon 3x5 mg Followed by 1x15 mg
Results
None posted
  1. 9 Nov 2022: Trial registered
  2. 15 Dec 2022: Trial started
  3. 17 Dec 2023: Trial completed

How the status changed

  1. 16 Nov 2026: First set: Phase 3 trial

About the treatment

Kind of treatment: Drug.

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.